Endothelial progenitor cell senescence is there a role for estrogen?
Author(s) -
Toshio Imanishi,
Hiroto Tsujioka,
Takashi Akasaka
Publication year - 2009
Publication title -
therapeutic advances in cardiovascular disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 33
eISSN - 1753-9455
pISSN - 1753-9447
DOI - 10.1177/1753944709353173
Subject(s) - senescence , progenitor cell , estrogen , medicine , endothelial progenitor cell , telomerase , microbiology and biotechnology , neovascularization , telomere , reactive oxygen species , endothelial stem cell , cancer research , stem cell , angiogenesis , in vitro , biology , biochemistry , dna , gene
Recent studies have demonstrated that aging or senescence constitutes a potential limitation to the ability of endothelial progenitor cells (EPCs) to sustain ischemic tissue repair. Excess amount of reactive oxygen species (ROS) is involved in senescence, causing defective neovascularization. Conversely, estrogens have been shown to accelerate recovery of the endothelium after vascular injury. Estrogen reduces EPC senescence through augmentation of telomerase activity. In addition, the inhibition of EPC senescence by estrogen in vitro may improve the functional activity of EPCs in a way that is important for potential cell therapy. This review describes current understanding of EPC senescence and the role of estrogen in preventing EPC senescence.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom